{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:48:54Z","timestamp":1790646534892,"version":"4.1.0"},"reference-count":112,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T00:00:00Z","timestamp":1583712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health","award":["K23AI143882 (PI - E.F.B.)"],"award-info":[{"award-number":["K23AI143882 (PI - E.F.B.)"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacy"],"abstract":"<jats:p>Pharmacists are at the forefront of dosing and monitoring medications eliminated by or toxic to the kidney. To evaluate the effectiveness and safety of these medications, accurate measurement of kidney function is paramount. The mainstay of kidney assessment for drug dosing and monitoring is serum creatinine (SCr)-based estimation equations. Yet, SCr has known limitations including its insensitivity to underlying changes in kidney function and the numerous non-kidney factors that are incompletely accounted for in equations to estimate glomerular filtration rate (eGFR). Serum cystatin C (cysC) is a biomarker that can serve as an adjunct or alternative to SCr to evaluate kidney function for drug dosing. Pharmacists must be educated about the strengths and limitations of cysC prior to applying it to medication management. Not all patient populations have been studied and some evaluations demonstrated large variations in the relationship between cysC and GFR. Use of eGFR equations incorporating cysC should be reserved for drug management in scenarios with demonstrated outcomes, including to improve pharmacodynamic target attainment for antibiotics or reduce drug toxicity. This article provides an overview of cysC, discusses evidence around its use in medication dosing and in special populations, and describes practical considerations for application and implementation.<\/jats:p>","DOI":"10.3390\/pharmacy8010035","type":"journal-article","created":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T11:59:36Z","timestamp":1583841576000},"page":"35","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Cystatin C: A Primer for Pharmacists"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2120-7380","authenticated-orcid":false,"given":"Hilary R.","family":"Teaford","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2146-5766","authenticated-orcid":false,"given":"Jason N.","family":"Barreto","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn J.","family":"Vollmer","sequence":"additional","affiliation":[{"name":"College of Pharmacy and Health Sciences, Drake University, Des Moines, IA 50311, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Rule","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, USA"},{"name":"Division of Epidemiology, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0996-1487","authenticated-orcid":false,"given":"Erin F.","family":"Barreto","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mayo Clinic, Rochester, MN 55905, USA"},{"name":"Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,3,9]]},"reference":[{"key":"ref_1","unstructured":"Seyffart, G. (2011). Seyffart\u2019s Directory of Drug Dosage in Kidney Disease, Dustri-Verlag Dr. Karl Feistle. [1st ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s40266-014-0187-z","article-title":"The use of estimated glomerular filtration rate for dose adjustment of medications in the elderly","volume":"31","author":"Elinder","year":"2014","journal-title":"Drugs Aging"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ccc.2006.02.003","article-title":"Drug-associated renal dysfunction","volume":"22","author":"Taber","year":"2006","journal-title":"Crit. Care Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1053\/j.ajkd.2013.03.027","article-title":"Update on cystatin C: Incorporation into clinical practice","volume":"62","author":"Shlipak","year":"2013","journal-title":"Am. J. Kidney Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1053\/j.ajkd.2011.07.022","article-title":"Use of clinical decision support systems for kidney-related drug prescribing: A systematic review","volume":"58","author":"Tawadrous","year":"2011","journal-title":"Am. J. Kidney Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1053\/j.ajkd.2010.09.006","article-title":"Using computerized provider order entry and clinical decision support to improve prescribing in patients with decreased GFR","volume":"56","author":"Galanter","year":"2010","journal-title":"Am. J. Kidney Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/cpt.729","article-title":"Assessment of Glomerular Filtration Rate in Health and Disease: A State of the Art Review","volume":"102","author":"Levey","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/phar.2149","article-title":"Innovative Use of Novel Biomarkers to Improve the Safety of Renally Eliminated and Nephrotoxic Medications","volume":"38","author":"Barreto","year":"2018","journal-title":"Pharmacotherapy"},{"key":"ref_9","unstructured":"(2013). The Kidney Disease: Improving Global Outcomes. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. Suppl., 3, 1\u2013150."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/ki.2008.638","article-title":"Factors other than glomerular filtration rate affect serum cystatin C levels","volume":"75","author":"Stevens","year":"2009","journal-title":"Kidney Int."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"397","DOI":"10.4158\/EP12282.OR","article-title":"Impact of Thyroid Function on Serum Cystatin C and Estimated Glomerular Filtration Rate: A Cross-Sectional Study","volume":"19","author":"Ye","year":"2013","journal-title":"Endocr. Pract."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/j.1523-1755.2004.00517.x","article-title":"Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement","volume":"65","author":"Knight","year":"2004","journal-title":"Kidney Int."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.atherosclerosis.2005.06.017","article-title":"Plasma cystatin-C and development of coronary heart disease: The PRIME Study","volume":"185","author":"Luc","year":"2006","journal-title":"Atherosclerosis"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1053\/j.ackd.2017.10.003","article-title":"Pragmatic Use of Kidney Function Estimates for Drug Dosing: The Tide Is Turning","volume":"25","author":"Hudson","year":"2018","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Modification of Diet in Renal Disease Study Group (1992). The Modification of Diet in Renal Disease Study: Design, Methods, and Results From the Feasibility Study. Am. J. Kidney Dis., 20, 18\u201333.","DOI":"10.1016\/S0272-6386(12)80313-1"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Chronic Kidney Disease Epidemiology Collaboration Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate","volume":"145","author":"Levey","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A New Equation to Estimate Glomerular Filtration Rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1681\/ASN.2010050479","article-title":"Estimated GFR associates with cardiovascular risk factors independently of measured GFR","volume":"22","author":"Mathisen","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/ndt\/gfx007","article-title":"Optimally predicting mortality with kidney function markers is not the same as optimally determining how kidney function predicts mortality","volume":"32","author":"Glassock","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_22","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) (2003). Draft Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal Function\u2014Study Design, Data Analysis, and Impact on Dosing and Labeling, CDER."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1053\/j.ajkd.2009.03.008","article-title":"Comparison of Drug Dosing Recommendations Based on Measured GFR and Kidney Function Estimating Equations","volume":"54","author":"Stevens","year":"2009","journal-title":"Am. J. Kidney Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/phar.2175","article-title":"Impact of Serum Cystatin C\u2013Based Glomerular Filtration Rate Estimates on Drug Dose Selection in Hospitalized Patients","volume":"38","author":"Peters","year":"2018","journal-title":"Pharmacotherapy"},{"key":"ref_25","first-page":"500","article-title":"Prediction of the Renal Elimination of Drugs With Cystatin C vs. Creatinine: A Systematic Review","volume":"94","author":"Barreto","year":"2019","journal-title":"Mayo Clin Proc."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"161","DOI":"10.5414\/CP201776","article-title":"Estimation of safe and effective dose of vancomycin in MRSA-infected patients using serum cystatin C concentrations","volume":"51","author":"Chen","year":"2013","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3346\/jkms.2013.28.1.48","article-title":"Serum cystatin C is a major predictor of vancomycin clearance in a population pharmacokinetic analysis of patients with normal serum creatinine concentrations","volume":"28","author":"Chung","year":"2013","journal-title":"J. Korean Med. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/FTD.0000000000000065","article-title":"Comparison of Equations With Estimate Renal Function to Predict Serum Vancomycin Concentration in Patients With Spinal Cord Injury\u2014Does the Use of Cystatin C Improve Accuracy?","volume":"36","author":"DeCarolis","year":"2014","journal-title":"Ther. Drug Monit."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1053\/j.ajkd.2016.11.016","article-title":"Cystatin C\u2013Guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project","volume":"69","author":"Frazee","year":"2017","journal-title":"Am. J. Kidney Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"R110","DOI":"10.1186\/cc13899","article-title":"Serum cystatin C predicts vancomycin trough levels better than serum creatinine in hospitalized patients: A cohort study","volume":"18","author":"Frazee","year":"2014","journal-title":"Crit. Care"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/01.ftd.0000211805.89440.3d","article-title":"Serum cystatin C for the prediction of glomerular filtration rate with regard to the dose adjustment of amikacin, gentamicin, tobramycin, and vancomycin","volume":"28","author":"Hermida","year":"2006","journal-title":"Ther. Drug Monit."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ijantimicag.2010.07.015","article-title":"Clearance of vancomycin during continuous infusion in Intensive Care Unit patients: Correlation with measured and estimated creatinine clearance and serum cystatin C","volume":"36","author":"Kees","year":"2010","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.clinbiochem.2007.01.008","article-title":"Serum cystatin C as a better marker of vancomycin clearance than serum creatinine in elderly patients","volume":"40","author":"Okamoto","year":"2007","journal-title":"Clin. Biochem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1211\/jpp.62.07.0011","article-title":"Usefulness of serum cystatin C to determine the dose of vancomycin in critically ill patients","volume":"62","author":"Suzuki","year":"2010","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0b013e31803bcfd2","article-title":"Estimation of the initial dose setting of vancomycin therapy with use of cystatin C as a new marker of renal function","volume":"29","author":"Tanaka","year":"2007","journal-title":"Ther. Drug Monit."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1128\/AAC.00661-09","article-title":"Population pharmacokinetic analysis of vancomycin using serum cystatin C as a marker of renal function","volume":"54","author":"Tanaka","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/jphp.13071","article-title":"A population pharmacokinetic model of vancomycin for dose individualization based on serum cystatin C as a marker of renal function","volume":"71","author":"Liu","year":"2019","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jiac.2017.12.002","article-title":"Population pharmacokinetics of teicoplanin in hospitalized elderly patients using cystatin C as an indicator of renal function","volume":"24","author":"Kasai","year":"2018","journal-title":"J. Infect. Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/jcpt.13029","article-title":"Development and comparison of population pharmacokinetic models of vancomycin in neurosurgical patients based on two different renal function markers","volume":"45","author":"Jing","year":"2020","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1046\/j.1523-1755.2003.00925.x","article-title":"Impact of thyroid dysfunction on serum cystatin C","volume":"63","author":"Pricker","year":"2003","journal-title":"Kidney Int."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cccn.2003.07.022","article-title":"Serum cystatin C is sensitive to small changes in thyroid function","volume":"338","author":"Wiesli","year":"2003","journal-title":"Clin. Chim. Acta"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1053\/j.ackd.2010.05.010","article-title":"Estimating the Glomerular Filtration Rate in Obese Adult Patients for Drug Dosing","volume":"17","author":"Pai","year":"2010","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1053\/j.ackd.2017.10.007","article-title":"Kidney Function in Obesity\u2014Challenges in Indexing and Estimation","volume":"25","author":"Chang","year":"2018","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.amjmed.2016.08.019","article-title":"Creatinine Clearance Is Not Equal to Glomerular Filtration Rate and Cockcroft-Gault Equation Is Not Equal to CKD-EPI Collaboration Equation","volume":"129","author":"Ortiz","year":"2016","journal-title":"Am. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1172\/JCI100207","article-title":"Studies of urea excretion. III: The Influence of Body Size on Urea Output","volume":"6","author":"McIntosh","year":"1928","journal-title":"J. Clin. Invest."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/PL00006751","article-title":"Poor correlation between body surface area and glomerular filtration rate","volume":"46","author":"Dooley","year":"2000","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/jcla.21648","article-title":"Indexing glomerular filtration rate to body surface area: Clinical consequences","volume":"28","author":"Rasmussen","year":"2014","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1093\/ndt\/gfp431","article-title":"Errors induced by indexing glomerular filtration rate for body surface area: Reductio ad absurdum","volume":"24","author":"Delanaye","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ndt\/gfm662","article-title":"Glomerular filtration rate\u2014What is the rationale and justification of normalizing GFR for body surface area?","volume":"23","author":"Geddes","year":"2008","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_50","first-page":"1","article-title":"Evaluating Muscle Mass by Using Markers of Kidney Function: Development of the Sarcopenia Index","volume":"45","author":"Kashani","year":"2016","journal-title":"Crit. Care Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s10620-017-4897-z","article-title":"Cystatin C Is a Gender-Neutral Glomerular Filtration Rate Biomarker in Patients with Cirrhosis","volume":"63","author":"Mindikoglu","year":"2018","journal-title":"Dig. Dis. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ncn3.11","article-title":"Creatinine\/cystatin C ratio as a surrogate marker of residual muscle mass in amyotrophic lateral sclerosis","volume":"1","author":"Tetsuka","year":"2013","journal-title":"Neurol. Clin. Neurosci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.nmd.2015.01.005","article-title":"Renal function in children and adolescents with Duchenne muscular dystrophy","volume":"25","author":"Braat","year":"2015","journal-title":"Neuromuscul. Disord."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jcf.2008.07.004","article-title":"GFR estimates using cystatin C are superior to serum creatinine in adult patients with cystic fibrosis","volume":"8","author":"Beringer","year":"2009","journal-title":"J. Cyst. Fibros."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/sc.2012.52","article-title":"Estimating the glomerular filtration rate using serum cystatin C levels in patients with spinal cord injuries","volume":"50","author":"Erlandsen","year":"2012","journal-title":"Spinal Cord"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1053\/j.ajkd.2013.07.014","article-title":"SCr and SCysC concentrations before and after traumatic amputation in male soldiers: A case-control study","volume":"63","author":"Thurlow","year":"2014","journal-title":"Am. J. Kidney Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.1093\/ndt\/gfq176","article-title":"Rapid detection of acute kidney injury by plasma cystatin C in the intensive care unit","volume":"25","author":"Nejat","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Aakj\u00e6r, M., Houlind, M., Treldal, C., Ankarfeldt, M.S., Jensen, P., Andersen, O., Iversen, E., Christrup, L., and Petersen, J. (2019). Differences in Kidney Function Estimates Based on Creatinine and\/or Cystatin C in Non-Traumatic Amputation Patients and Their Impact on Drug Prescribing. J. Clin. Med., 8.","DOI":"10.3390\/jcm8010089"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3892\/br.2012.21","article-title":"Effect of dexamethasone on extracellular secretion of cystatin C in cancer cell lines","volume":"1","author":"Yamawaki","year":"2013","journal-title":"Biomed. Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1159\/000469715","article-title":"Dexamethasone modifies cystatin c-based diagnosis of acute kidney injury during cisplatin-based chemotherapy","volume":"42","author":"Pianta","year":"2017","journal-title":"Kidney Blood Press. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00280-018-3762-x","article-title":"The value of serum cystatin C in early evaluation of renal insufficiency in patients undergoing chemotherapy: A systematic review and meta-analysis","volume":"83","author":"He","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Hammouda, N.E., Salah El-Din, M.A., El-Shishtawy, M.M., and El-Gayar, A.M. (2017). Serum Cystatin C as a Biomarker in Diffuse Large B-Cell Lymphoma. Sci. Pharm., 85.","DOI":"10.3390\/scipharm85010009"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.canlet.2006.07.004","article-title":"Cystatin C as a potential marker for relapse in patients with non-Hodgkin B-cell lymphoma","volume":"248","author":"Kos","year":"2007","journal-title":"Cancer Lett."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/ejh.12164","article-title":"The chronic kidney disease epidemiology collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EPI-CysC","volume":"91","author":"Terpos","year":"2013","journal-title":"Eur. J. Haematol."},{"key":"ref_65","first-page":"505","article-title":"Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: Relation to prognosis","volume":"6","author":"Kos","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"ref_66","first-page":"1815","article-title":"Cathepsins B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients","volume":"3","author":"Kos","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s12185-012-1049-2","article-title":"Prognostic significance of serum cystatin C in multiple myeloma","volume":"95","author":"Langer","year":"2012","journal-title":"Int. J. Hematol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/ajh.25117","article-title":"Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management","volume":"93","author":"Rajkumar","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3324\/haematol.2008.000638","article-title":"Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration","volume":"94","author":"Terpos","year":"2009","journal-title":"Haematologica"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.2165\/00003088-200544120-00009","article-title":"Cystatin C as a new covariate to predict renal elimination of drugs: Application to carboplatin","volume":"44","author":"Thomas","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s10157-015-1115-1","article-title":"Renal function evaluation in patients with cancer who were scheduled to receive carboplatin or S-1","volume":"19","author":"Shibata","year":"2015","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Cavalcanti, E., Barchiesi, V., Cerasuolo, D., Di Paola, F., Cantile, M., Cecere, S.C., Pignata, S., Morabito, A., Costanzo, R., and Di Maio, M. (2016). Correlation of Serum Cystatin C with Glomerular Filtration Rate in Patients Receiving Platinum-Based Chemotherapy. Anal. Cell. Pathol.","DOI":"10.1155\/2016\/4918325"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00280-017-3326-5","article-title":"Estimation of glomerular filtration rate in cancer patients with abnormal body composition and relation with carboplatin toxicity","volume":"80","author":"Bretagne","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1002\/pbc.25137","article-title":"Assessment of renal function during high-dose methotrexate treatment in children with acute lymphoblastic leukemia","volume":"61","author":"Ylinen","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1158\/1078-0432.CCR-04-2086","article-title":"Serum cystatin C is a better marker of topotecan clearance than serum creatinine","volume":"11","author":"Hoppe","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Barreto, J.N., McClanahan, A.L., Rule, A.D., Thompson, C.A., and Frazee, E. (2018). Incorporating Cystatin C to Predict Methotrexate Elimination in Patients with CNS Lymphoma and Suspicious Renal Function. Case Rep. Hematol.","DOI":"10.1155\/2018\/7169897"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/ajco.12312","article-title":"Comparative performances of the new chronic kidney disease epidemiology equations incorporating cystatin C for use in cancer patients","volume":"11","author":"Florkowski","year":"2015","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1080\/0886022X.2019.1638798","article-title":"Corticosteroids significantly increase cystatin C levels in the plasma by promoting cystatin C production in rats","volume":"41","author":"Zhu","year":"2019","journal-title":"Ren. Fail."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3109\/00365519509110261","article-title":"Promoter-mediated, dexamethasone-induced increase in cystatin c production by hela cells","volume":"55","author":"Grubb","year":"1995","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cccn.2005.01.022","article-title":"Early effects of methylprednisolone infusion on serum cystatin C in patients with severe Graves\u2019 ophthalmopathy [2]","volume":"356","author":"Manetti","year":"2005","journal-title":"Clin. Chim. Acta"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0009-8981(00)00298-9","article-title":"Serum cystatin C, a potent inhibitor of cysteine proteinases, is elevated in asthmatic patients","volume":"300","author":"Cimerman","year":"2000","journal-title":"Clin. Chim. Acta"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"203","DOI":"10.7754\/Clin.Lab.2015.150701","article-title":"Corticosteroids significantly increase serum cystatin c concentration without affecting renal function in symptomatic heart failure","volume":"62","author":"Zhai","year":"2016","journal-title":"Clin. Lab."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00467-005-2075-6","article-title":"Influence of commonly used drugs on the accuracy of cystatin C-derived glomerular filtration rate","volume":"21","author":"Foster","year":"2006","journal-title":"Pediatr. Nephrol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s12253-009-9243-0","article-title":"Differential effect of corticosteroids on serum cystatin C in thrombocytopenic purpura and leukemia","volume":"16","author":"Bardi","year":"2010","journal-title":"Pathol. Oncol. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1373\/clinchem.2007.094946","article-title":"Effect of Corticosteroid Therapy on Low-Molecular\u2013Weight Protein Markers of Kidney Function","volume":"53","author":"Bokenkamp","year":"2007","journal-title":"Clin. Chem."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00467-011-2073-9","article-title":"Comparing cystatin C and creatinine in the diagnosis of pediatric acute renal allograft dysfunction","volume":"27","author":"Slort","year":"2012","journal-title":"Pediatr. Nephrol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.cca.2018.10.022","article-title":"Utility of estimated glomerular filtration rate using cystatin C and its interpretation in patients with rheumatoid arthritis under glucocorticoid therapy","volume":"487","author":"Nozawa","year":"2018","journal-title":"Clin. Chim. Acta"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/bcp.12501","article-title":"The performance of contemporary cystatin C-based GFR equations in predicting gentamicin clearance","volume":"79","author":"Chin","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e13182","DOI":"10.1111\/ctr.13182","article-title":"The Sarcopenia Index: A Novel Measure of Muscle Mass in Lung Transplant Candidates","volume":"32","author":"Kashani","year":"2018","journal-title":"Clin. Transplant."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/sj.ki.5000073","article-title":"Glomerular filtration rate estimated by cystatin C among different clinical presentations","volume":"69","author":"Rule","year":"2006","journal-title":"Kidney Int."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1093\/ndt\/gfh341","article-title":"Time course of low molecular weight proteins in the early kidney transplantation period\u2014Influence of corticosteroids","volume":"19","author":"Gerhardt","year":"2004","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_92","first-page":"1015","article-title":"Value of serum cystatin C as a marker of renal function in the early post kidney transplant period","volume":"20","author":"Geramizadeh","year":"2009","journal-title":"Saudi J. Kidney Dis. Transpl."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s11255-013-0624-7","article-title":"Cystatin C and serum creatinine as predictors of kidney graft outcome","volume":"46","author":"Lezaic","year":"2014","journal-title":"Int. Urol. Nephrol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"E177","DOI":"10.1111\/ctr.12082","article-title":"Cystatin C and albuminuria as predictors of long-term allograft outcomes in kidney transplant recipients","volume":"27","author":"Rodrigo","year":"2013","journal-title":"Clin. Transplant."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1093\/clinchem\/46.8.1206","article-title":"Plasma cystatin C is superior to 24-h creatinine clearance and plasma creatinine for estimation of glomerular filtration rate 3 months after kidney transplantation [1]","volume":"46","author":"Thervet","year":"2000","journal-title":"Clin. Chem."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000357594","article-title":"Cystatin C Enhances Glomerular Filtration Rate Estimating Equations in Kidney Transplant Recipients","volume":"39","author":"Kukla","year":"2014","journal-title":"Am. J. Nephrol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1111\/ajt.13258","article-title":"KDIGO Guidelines and Kidney Transplantation: Is the Cystatin-C Based Recommendation Relevant?","volume":"15","author":"Masson","year":"2015","journal-title":"Am. J. Transplant."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/ndt\/gfs498","article-title":"Accuracy of cystatin C-based estimates of glomerular filtration rate in kidney transplant recipients: A systematic review","volume":"28","author":"Harman","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/j.transproceed.2012.07.032","article-title":"A Comparison Between Serum Creatinine and Cystatin C-Based Equations for Estimation of Graft Function","volume":"44","author":"Malheiro","year":"2012","journal-title":"Transplant. Proc."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.transproceed.2017.12.004","article-title":"Prospective Comparison of Equations Based on Creatinine and Cystatin C for the Glomerular Filtration Rate Estimation in Chinese Renal Transplant Recipients","volume":"50","author":"Tang","year":"2018","journal-title":"Transplant. Proc."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1681\/ASN.2005050512","article-title":"Estimating glomerular filtration rate in kidney transplantation: A comparison between serum creatinine and cystatin C-based methods","volume":"16","author":"White","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s10157-013-0811-y","article-title":"How to estimate kidney function in kidney transplant recipients with mild to moderate kidney impairment: Comparison of estimated glomerular filtration (eGFR) values between creatinine-based GFR equations and cystatin C-based GFR equations for Japanese pop","volume":"18","author":"Tsujita","year":"2014","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1053\/j.ajkd.2015.09.022","article-title":"Creatinine Versus Cystatin C for Estimating GFR in Patients with Liver Cirrhosis","volume":"67","author":"Torre","year":"2016","journal-title":"Am. J. Kidney Dis."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Krones, E., Fickert, P., Zitta, S., Neunherz, S., Artinger, K., Reibnegger, G., Durchschein, F., Wagner, D., Stojakovic, T., and Stadlbauer, V. (2015). The chronic kidney disease epidemiology collaboration equation combining creatinine and cystatin C accurately assesses renal function in patients with cirrhosis. BMC Nephrol., 16.","DOI":"10.1186\/s12882-015-0188-0"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"243","DOI":"10.21037\/atm.2019.05.22","article-title":"Pretransplant renal function evaluated by serum cystatin C was associated with mortality after liver transplantation: A single-center experience","volume":"7","author":"Ding","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.transproceed.2011.01.103","article-title":"Cystatin C level as a predictor of death and cardiovascular events after liver transplantation","volume":"43","author":"Bernal","year":"2011","journal-title":"Transplant. Proc."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.transproceed.2018.01.049","article-title":"Pretransplantation Cystatin C, but not Creatinine, Predicts 30-day Cardiovascular Events and Mortality in Liver Transplant Recipients With Normal Serum Creatinine Levels","volume":"50","author":"Kwon","year":"2018","journal-title":"Transplant. Proc."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/liv.12989","article-title":"Pretransplant renal function according to CKD-EPI cystatin C equation is a prognostic factor of death after liver transplantation","volume":"36","author":"Uguen","year":"2016","journal-title":"Liver Int."},{"key":"ref_109","first-page":"239","article-title":"Comparison of cystatin C and NGAL in early diagnosis of acute kidney injury after heart transplantation","volume":"21","author":"Kautzner","year":"2016","journal-title":"Ann. Transplant."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.clinbiochem.2017.01.008","article-title":"Predictive performance of different kidney function estimation equations in lung transplant patients","volume":"50","author":"Degen","year":"2017","journal-title":"Clin. Biochem."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/gim.2012.157","article-title":"Implementing genomic medicine in the clinic: The future is here","volume":"15","author":"Manolio","year":"2013","journal-title":"Genet. Med."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Zhi, M., Ding, E.L., Theisen-Toupal, J., Whelan, J., and Arnaout, R. (2013). The landscape of inappropriate laboratory testing: A 15-year meta-analysis. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0078962"}],"container-title":["Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2226-4787\/8\/1\/35\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:05:29Z","timestamp":1760173529000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2226-4787\/8\/1\/35"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,9]]},"references-count":112,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,3]]}},"alternative-id":["pharmacy8010035"],"URL":"https:\/\/doi.org\/10.3390\/pharmacy8010035","relation":{},"ISSN":["2226-4787"],"issn-type":[{"value":"2226-4787","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,9]]}}}